Dr. Lo Re is an infectious diseases physician and clinical epidemiologist whose areas of interest include epidemiology of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, HIV-viral hepatitis coinfection, and drug-induced liver injury. Dr. Lo Re’s research has evaluated risk factors for end-stage liver disease (ESLD) and hepatocellular carcinoma among HIV/HCV-coinfected patients; developed prognostic models for ESLD among HIV/HCV patients; and examined extra-hepatic effects of chronic HCV, including cardiovascular disease and metabolic bone disease. Current studies focus on elucidating the mechanisms for hepatocellular carcinoma in HIV.

Dr. Lo Re is also interested in HIV/HBV coinfection. His recent work in this area has focused on the incidence of HBV DNA suppression during tenofovir-based antiretroviral therapy and determinants of liver complications among HIV/HBV patients on HBV-active antiretroviral therapy. 

Dr. Lo Re has conducted phamacoepidemiologic research examining adherence to antiviral therapy for chronic HCV infection. His work in the area of drug-induced liver injury has focused on evaluating the epidemiology of drug-induced acute liver failure, development and validation of prognostic models for acute liver failure among patients with drug-induced liver injury, and evaluating the risk of acute liver injury associated with antireroviral, antimicrobial, and antifungal drugs.

From a methodologic standpoint, Dr. Lo Re has pioneered the use of electronic healthcare databases to evaluate acute and chronic liver diseases. Dr. Lo Re has also developed methods to evaluate the safety of medications following market release.